In early January 2026, UBS upgraded Bristol-Myers Squibb after highlighting its broad drug pipeline, new clinical trial ...
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic ...
AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board Seasoned executive with extensive ...
Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, "Automotive Battery ...
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant ...
OXFORD, England, Jan. 6, 2026 /PRNewswire/ -- Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been ...
The Building Controls Industry Association (BCIA) has added exceptional experience to its Management Committee as it ...
The global amyloidosis treatment market is on a trajectory of significant expansion, driven by heightened disease awareness, ...
Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...
Dallas, this week highlighted progress under the Trump Administration to lower prescription drug prices, following recent commitments from pharmaceutical manufacturers to adopt Most Favored Nation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback